Enanta Pharmaceuticals, Inc. (ENTA)

NASDAQ: ENTA · Real-Time Price · USD

14.15

+0.07 (0.50%)

At close: Aug 26, 2026, 4:00 PM EDT

14.15

0.00 (0.00%)

After-hours: Aug 26, 2026, 7:30 PM EDT

Enanta Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Cash & Equivalents	33.42	32.3	37.23	85.39	43.99	57.21
Short-Term Investments	156.09	156.57	210.95	284.52	205.24	186.8
Cash & Short-Term Investments	189.51	188.86	248.19	369.91	249.23	244
Cash Growth	-7.16%	-23.90%	-32.91%	48.42%	2.14%	-36.89%
Accounts Receivable	6.53	6.88	6.65	8.61	20.32	23.58
Other Receivables	-	-	32	31	28.72	37.26
Receivables	6.53	6.88	38.65	39.62	49.04	60.83
Prepaid Expenses	7.58	8.59	12.41	13.26	13.45	14.19
Restricted Cash	-	-	0.61	-	-	-
Total Current Assets	203.62	204.34	299.85	422.79	311.71	319.02
Property, Plant & Equipment	67.79	72.94	73.35	34.71	29.75	10.65
Long-Term Investments	21.99	-	-	-	29.29	108.42
Other Long-Term Assets	3.47	3.45	3.45	4.77	4.66	0.7
Total Assets	296.87	280.73	376.65	462.28	375.41	438.79

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Accounts Payable	3.29	1.95	8	4.1	6	9.54
Accrued Expenses	10.18	12.75	13.55	18.34	20.94	22.43
Current Portion of Long-Term Debt	36.78	30.71	34.46	35.08	-	-
Current Portion of Leases	3.91	3.15	1.52	5.28	2.89	4.2
Total Current Liabilities	54.17	48.56	57.54	62.79	29.83	36.17
Long-Term Debt	89.6	112.44	136.13	160.85	1.42	1.51
Long-Term Leases	51.75	54.76	53.94	21.24	22.37	1.13
Other Long-Term Liabilities	0.29	0.26	0.23	0.66	0.45	0.56
Total Liabilities	195.8	216.02	247.84	245.54	54.08	39.36

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Common Stock	0.29	0.21	0.21	0.21	0.21	0.2
Additional Paid-In Capital	551.16	469.77	451.34	424.69	398.03	351.03
Retained Earnings	-449.46	-404.93	-323.04	-207	-73.18	48.58
Comprehensive Income & Other	-0.93	-0.34	0.3	-1.17	-3.72	-0.38
Shareholders' Equity	101.07	64.72	128.81	216.74	321.33	399.43
Total Liabilities & Equity	296.87	280.73	376.65	462.28	375.41	438.79

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Total Debt	182.04	201.06	226.06	222.44	26.69	6.84
Net Cash (Debt)	29.45	-12.19	22.13	147.47	251.83	345.58
Net Cash Growth	-	-	-85.00%	-41.44%	-27.13%	-15.65%
Net Cash Per Share	1.09	-0.57	1.05	7.03	12.22	17.13
Filing Date Shares Outstanding	29.13	28.86	21.19	21.06	20.8	20.32
Total Common Shares Outstanding	29.12	21.39	21.19	21.06	20.79	20.24
Working Capital	149.45	155.78	242.32	360	281.89	282.85
Book Value Per Share	3.47	3.03	6.08	10.29	15.46	19.74
Tangible Book Value	101.07	64.72	128.81	216.74	321.33	399.43
Tangible Book Value Per Share	3.47	3.03	6.08	10.29	15.46	19.74
Machinery	-	20.39	19.92	19.14	16.79	16.32
Construction In Progress	-	-	22.75	1.27	2.56	0.02
Leasehold Improvements	-	38.2	13.98	13.8	7.28	7.14

SEC Filings: 10-K · 10-Q